A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA

Gene Therapy

Volumn 6, Issue 2, 1999, Pages 300-304

  Hombach, A ^a   Koch, D ^a   Sircar, R ^a   Heuser, C ^a   Diehl, V ^a   Kruis, W ^b   Pohl, C ^b   Abken, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Evangelisches Krankhs Koln Kalk   (Germany)

Author keywords

Chimeric T cell receptor; Membrane bound CEA; ScFv

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CHIMERIC PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; TUMOR CELL;

CARCINOEMBRYONIC ANTIGEN; GENE THERAPY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERLEUKIN-2; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0032993494     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300813     Document Type: Article

References (17)

1. Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 1992; 6: 3370-3378.
2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
3. Hwu P et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178: 361-366.
4. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91: 4318-4322.
5. Hwu P et al. In vivo activity of T cells redirected with chimeric antibody/T cell receptor genes. Cancer Res 1995; 55: 3369-3373.
6. Eshhar Z et al. The T-body approach: potential for cancer immunotherapy. Semin Immunopathol 1996; 18: 199-209.
7. Abken H, Hombach A, Reinhold U, Ferrone S. Can combined T cell and antibody-based immunotherapy outsmart tumor cells? Immunol Today 1998; 19: 2-5.
8. Gross G et al. Chimeric T cell receptors specific to a B-lymphoma idiotype: a model for tumor immunotherapy. Biochem Soc Transact 1995; 23: 1079-1083.
9. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 66-73.
10. Bosslet K et al. Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA). Int J Cancer 1985; 36: 75-84.
11. Murakami M et al. Binding reactivity of monoclonal anti-carcinoembryonic antigen (CEA) antibodies with cell membrane-bound CEA and with free CEA in solution. Immunol Invest 1996; 25: 23-35.
12. Kaulen H et al. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. Year Immunol 1993; 7: 106-109.
13. Bruynk A, Seemann G, Bosslet K. Charcterization of a humanized bispecific monoclonal antibody for cancer therapy. Br J Cancer 1993; 67: 436-440.
14. Shu L, Qi SF, Schlom J, Kashmiri SVS. Secretion of a single-gene encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci USA 1993; 90: 7995-7999.
15. Pohl C et al. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma. Int J Cancer 1993; 54: 418-425.
16. Blomberg K, Ulfstedt AC. Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J Immunol Meth 1993; 160: 27-34.
17. Moertel CG et al. The pre-operative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986; 58: 603-610.